Ignite Creation Date:
2024-05-06 @ 3:50 PM
Last Modification Date:
2024-10-26 @ 1:58 PM
Study NCT ID:
NCT04776876
Status:
WITHDRAWN
Last Update Posted:
2021-09-29
First Post:
2021-02-08
Brief Title:
Retifanlimab INCMGA00012 and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-03-01
Start Date Type:
ESTIMATED
Primary Completion Date:
2021-09-02
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-09-02
Completion Date Type:
ACTUAL
First Submit Date:
2021-02-08
First Submit QC Date:
February 25 2021
Study First Post Date:
2021-03-02
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-09-23
Last Update Post Date:
2021-09-29
Last Update Post Date Type:
ACTUAL